Stemline Therapeutics Present Clinical Trial Results of Synthetic Peptide Vaccine for Brain Cancer at SNO Annual Meeting

Stemline Therapeutics STML announced today that clinical trial results of a synthetic peptide vaccine for brain cancer, now being developed as SL-701, will be presented by investigators from the University of Pittsburgh at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco, California on November 21-24, 2013. SL-701 is a subcutaneously-administered cancer vaccine comprised of multiple synthetic peptides corresponding to targets on tumor bulk and cancer stem cells (CSCs). The synthetic peptide vaccine developed by the University of Pittsburgh has previously demonstrated single-agent clinical efficacy, including complete responses (CRs), in Phase 1/2 trials in both adults and children with high-grade glioma (HGG), including glioblastoma multiforme (GBM). Based on these results, Stemline, who licensed patent rights relating to the Pitt vaccine from the University of Pittsburgh, is planning registration-directed programs in both adults and children with HGG. According to a research abstract published on the SNO meeting website, University of Pittsburgh investigators will report on the safety and immunological responses achieved with the Pitt vaccine in an additional indication, adults with newly diagnosed or recurrent See full press release